# Edenlux Launches Eye-Strain Gadget in U.S. Market
In a bold move to combat the growing epidemic of digital eye strain, South Korean innovator Edenlux is officially bringing its groundbreaking Otus personal eye-trainer to the U.S. market. This AI-powered wearable device promises to revolutionize vision therapy by automating eye muscle training, helping users fight fatigue from endless screen time while going about their daily routines.[1][2]
How Otus Tackles Eye Strain with AI and Vision Therapy
Edenlux's Otus device automates Vision Therapy, a proven exercise regimen that repeatedly contracts and relaxes eye muscles to relieve stress and enhance strength. Equipped with eight special optical lenses that rotate over 60 times in just five minutes, Otus delivers personalized training without interrupting your activities—whether you're watching videos, reading, or working.[1][3]
The wearable's open-view design allows for comfortable daily use, even with prescription lenses, making it ideal for prolonged screen exposure that plagues modern lifestyles. Users simply wear the lightweight gadget, and it automatically analyzes eye condition via AI and IoT technology, plans customized sessions, and tracks progress through a Bluetooth-connected app featuring detailed reports and engaging games.[1][2]
Developed by the South Korean startup, Otus has already proven its mettle with a CES 2023 Innovation Award and over $10 million in global sales, including strong uptake by U.S. clinics impressed by its 90% user adherence rates for at-home training.[2]
Edenlux's Road to U.S. Success: From Crowdfunding to Clinic Adoption
Edenlux first tested Otus waters with successful crowdfunding campaigns on Japan's Makuake platform and Indiegogo, where backers raved about its ease and effectiveness in addressing eye health issues from electronics and media overuse.[1][3] Now, with U.S. expansion in full swing, vision therapy centers and clinics are snapping it up for its time-saving results, as noted by Edenlux's marketing manager: “Clinics want tools that save time and deliver results. OTUS does both.”[2]
The device's non-medical wellness focus—explicitly not designed to treat conditions—positions it perfectly for the booming eye strain relief market, where Americans spend over 10 hours daily on screens, leading to skyrocketing cases of fatigue and blurry vision.[2] Edenlux dubs Otus “a ray of ‘light’ for humanity’s eye health,” a claim backed by its track record in Asia and growing stateside partnerships.[2]
Why Otus Stands Out in the Eye Wellness Revolution
What sets Otus apart is its hands-free automation: no manual exercises required. The app provides real-time insights into eye health, post-training improvements, and fun gamified sessions to boost engagement. This seamless integration of AI, rotating lenses, and IoT makes eye strain gadgets accessible to everyone, from remote workers to gamers.[1][2][3]
As screen dependency surges, Otus arrives at a pivotal moment, empowering users to strengthen their eyes proactively. U.S. clinics report higher patient compliance thanks to its compatibility with everyday tasks like YouTube viewing or reading, solidifying Edenlux's foothold in the competitive wellness tech space.[2]
Frequently Asked Questions
What is Otus by Edenlux?
Otus is a wearable **eye-trainer** device that uses AI-powered **Vision Therapy** to relieve eye strain through automated muscle contraction and relaxation exercises via rotating optical lenses.[1][2]
How does Otus work to reduce eye strain?
Users wear the open-view device, which automatically analyzes eye condition, delivers five-minute training sessions with 60+ lens rotations, and tracks progress via a Bluetooth app with reports and games.[1][3]
Is Otus a medical device?
No, Otus is a wellness device not designed or intended to treat any medical conditions; it's focused on eye muscle training and stress relief.[1]
Has Otus launched in the U.S. market?
Yes, Edenlux is expanding Otus into the U.S. with clinic partnerships and growing adoption, building on its **CES 2023** award and $10M+ global sales.[2]
Can Otus be used with prescription lenses?
Yes, its open-view design supports prescription lenses, allowing comfortable integration into daily routines like screen time or reading.[2]
Where did Otus originate and what's its track record?
Developed by South Korea's Edenlux, Otus succeeded on Japan's Makuake and Indiegogo campaigns before U.S. entry, with positive user feedback and high adherence in clinics.[1][2][3]
🔄 Updated: 1/27/2026, 1:50:42 AM
**BREAKING: FDA Grants IDE Approval for EyeYon Medical's EndoArt Eye Device Ahead of U.S. Trial Launch**
The U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for EyeYon Medical's EndoArt synthetic corneal implant, enabling the first multicenter human clinical trial in the U.S. for treating chronic corneal edema, led by Prof. Francis Mah of Scripps Clinic with at least 10 leading surgeons.[1][5] EyeYon CEO Nahum Ferera stated, “It’s an important first step that requires the technology to go through strict testing in the US, including checks for safety, effectiveness, and long-term monitoring,
🔄 Updated: 1/27/2026, 2:00:49 AM
**BREAKING: Edenlux's Otus Eye-Trainer Sparks Global Buzz with U.S. Launch.** South Korean startup Edenlux's AI-powered Otus device, boasting over **$10M in global sales** and a **CES 2023 Innovation Award**, is expanding into the U.S. market via clinic partnerships, where **90% patient adherence** has clinics "snapping it up" after huge successes on Japan's Makuake platform[1][2][3]. Internationally, Edenlux hails Otus as *"a ray of ‘light’ for humanity’s eye health"* amid rising screen-induced eye strain, with marketing manager David noting, *"Clinics want tools that save time and deliver results—OTUS does bot
🔄 Updated: 1/27/2026, 2:10:43 AM
**Edenlux's Eyeary advances eye-strain relief with 144 diopter focal points—24 times more precise than Otus's five—enabling finer ciliary muscle training via Bluetooth-paired AI that customizes regimens from user data across age, gender, and vision profiles.** [1] The sleek glasses-like design promises to halve Otus's 12-month timeline for reducing reading glass dependence to six months, per CEO Park, building on Otus's $10M revenue and CES 2023 award amid U.S. clinic adoption for 90% patient adherence. [1][3] Launching via Indiegogo by late March as an FDA wellness device, Eyeary signals scalable vision therapy integration with smartphones fro
🔄 Updated: 1/27/2026, 2:20:43 AM
**BREAKING: FDA Grants IDE Approval for EyeYon Medical's EndoArt Eye Device Ahead of U.S. Trial Launch**
The U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for EyeYon Medical's EndoArt synthetic corneal implant, enabling the first multicenter human clinical trial in the U.S. for chronic corneal edema treatment, led by Prof. Francis Mah of Scripps Clinic with at least 10 leading surgeons.[1][5] EyeYon CEO Nahum Ferera stated, “It’s an important first step that requires the technology to go through strict testing in the US, including checks for safety, effectiveness, and long-term monitoring,
🔄 Updated: 1/27/2026, 2:30:47 AM
**LIVE NEWS UPDATE: Edenlux Eyeary U.S. Launch Sparks Buzz Among Screen-Fatigued Consumers**
Early U.S. reactions to South Korean startup Edenlux's Eyeary eye-strain gadget—slated for Indiegogo in late March—mirror the blockbuster response to its predecessor Otus, which racked up $10 million in global sales, a CES 2023 Innovation Award, and 90% patient adherence in clinics.[1][4] Consumers praise its sleek glasses-like design with 144 diopter focal points for faster vision training (potentially halving Otus's 12-month timeline to six months), while one Edenlux exec noted, *"Clinics want tools that save time and deliver results—Eyeary doe
🔄 Updated: 1/27/2026, 2:40:44 AM
**NEWS UPDATE: Edenlux Launches Eye-Strain Gadget in U.S. Market**
South Korean startup Edenlux is launching its second eye-strain wellness device, **Eyeary**, via Indiegogo by late March, featuring **144 diopter focal points** for precise muscle training—far surpassing the **five** in its predecessor Otus—and promising to halve reading glass dependence from **12 months to six**, per CEO Park.[1] U.S. clinics are embracing the tech, with **90% patient adherence** during home use and over **$10M** in Otus global sales plus a **CES 2023 Innovation Award**; marketing manager David notes, *“Clinics want tools that save time an
🔄 Updated: 1/27/2026, 2:50:44 AM
**WASHINGTON (Live Update) —** No specific regulatory response from the U.S. Food and Drug Administration (FDA) or other government bodies has been reported regarding Edenlux's launch of Eyeary, its eye-strain relief gadget targeting the U.S. market. In the broader eye care device landscape, the FDA recently granted an Investigational Device Exemption (IDE) to EyeYon Medical's EndoArt synthetic corneal implant, enabling a multicenter U.S. trial starting March 2026 with at least 10 leading surgeons, as stated by CEO Nahum Ferera: “It’s an important first step that requires the technology to go through strict testing in the US, including checks for safety, effectiveness, and long-term monitorin
🔄 Updated: 1/27/2026, 3:00:50 AM
**Edenlux U.S. Launch Sparks Buzz for Eyeary Eye-Strain Gadget**
Consumers are rallying around Edenlux's upcoming Eyeary device, with its predecessor Otus boasting $10 million in global sales and 90% patient adherence in U.S. clinics, where providers praise its AI-driven vision therapy.[1][3] "Clinics want tools that save time and deliver results—OTUS does both," said David, Edenlux’s marketing manager, as early feedback highlights its comfort for 10+ hour screen days.[3] Japanese crowdfunding users reported "very positive" results, fueling excitement ahead of Eyeary's late March Indiegogo debut.[2][4]
🔄 Updated: 1/27/2026, 3:10:44 AM
**Edenlux's U.S. launch of Eyeary disrupts the eye-strain wellness market by outpacing rivals with 144 diopter focal points—versus Otus's original 5—and halving user training time from 12 to 6 months, per CEO Park.** Backed by $10 million in Otus global sales and CES 2023 accolades, the lighter, app-connected glasses challenge U.S. clinics adopting vision therapy tools, as Edenlux eyes Apple/Samsung integrations amid its $99 million in prior funding.[1][3] "Clinics want tools that save time and deliver results—Eyeary does both," echoes marketing head David on the competitive edge.[3]
🔄 Updated: 1/27/2026, 3:20:45 AM
**BREAKING: Edenlux's Eyeary Eye-Strain Gadget Hits U.S. Spotlight with Expert Backing**
South Korean startup Edenlux is launching its second wellness device, **Eyeary**, via Indiegogo by late March, featuring 144 diopter focal points—up from the Otus model's five—and promising to halve reading glasses dependence from 12 to six months, per CEO Park[1]. U.S. clinics are embracing the tech, with marketing manager David stating, *“Clinics want tools that save time and deliver results—OTUS does both,”* amid $10M+ in Otus global sales and CES 2023 acclaim for its AI-driven vision therapy boosting patient adherence to 90%
🔄 Updated: 1/27/2026, 3:30:44 AM
**BREAKING: No Regulatory Response to Edenlux Eyeary Launch**
Edenlux has launched Eyeary, its eye-strain recovery gadget, into the U.S. market without any noted FDA clearance, approval, or government response as of January 27, 2026[7]. Unlike recent ophthalmic devices such as EyeYon Medical's EndoArt synthetic corneal implant—which received FDA Investigational Device Exemption (IDE) approval for a multicenter U.S. trial led by Prof. Francis Mah, involving at least 10 surgeons[1][5]—Eyeary appears to proceed commercially absent similar regulatory milestones or breakthrough designations[4]. EyeYon CEO Nahum Ferera highlighted the IDE as "an importan
🔄 Updated: 1/27/2026, 3:40:44 AM
**LIVE UPDATE: Edenlux's Eyeary U.S. Launch Draws Expert Praise for AI-Driven Eye Training**
Industry experts laud Edenlux's Eyeary, launching via Indiegogo by late March, as a leap over its predecessor Otus—which generated $10M in revenue and CES 2023 honors—thanks to 144 diopter focal points (vs. Otus's 5) and AI-customized programs predicting improvements in six months.[1][3] U.S. clinics are adopting the tech rapidly, with marketing manager David noting, “Clinics want tools that save time and deliver results. OTUS does both,” boosting patient adherence to 90% during daily screen time.[3] Analysts highlight Edenlu
🔄 Updated: 1/27/2026, 3:50:43 AM
**Edenlux U.S. Launch Shakes Up Eye-Strain Device Market with Eyeary's Superior Specs.** South Korea's Edenlux is debuting its second-generation Eyeary device via Indiegogo in late March, boasting 144 diopter focal points—29 times more precise than the 5 in its predecessor Otus—and halving reading glass dependency from 12 to 6 months, per CEO Park[1]. Otus, already generating $10M in global sales and adopted by U.S. clinics with 90% patient adherence, signals Edenlux's edge over manual vision therapy rivals, as the firm eyes partnerships with Apple or Samsung to embed tech in smartphones[1][3].
🔄 Updated: 1/27/2026, 4:00:53 AM
**Edenlux U.S. Launch Shakes Up Eye-Strain Tech Rivalry.** South Korea's Edenlux is debuting its sleeker Eyeary device—featuring **144 diopter focal points** versus the original Otus's mere **5**—via Indiegogo in late March, slashing reading glass dependency from **12 months to 6 months** per CEO Park, intensifying competition against screen-fatigue gadgets from firms like those partnering with Apple or Samsung[1]. With Otus already driving **$10 million** in global sales and CES 2023 accolades while U.S. clinics adopt it at **90% adherence rates**, Eyeary's AI-customized training and glasses-like design could erode marke
🔄 Updated: 1/27/2026, 4:10:43 AM
**WASHINGTON—** No specific regulatory response from the U.S. Food and Drug Administration (FDA) or other government bodies has been reported regarding Edenlux's launch of Eyeary, its eye-strain relief gadget targeting the U.S. market.[7] This contrasts with recent FDA actions in ophthalmology, such as granting an Investigational Device Exemption (IDE) to EyeYon Medical for its EndoArt synthetic corneal implant, enabling a multicenter U.S. trial led by Prof. Francis Mah starting March 2026 with at least 10 surgeons.[1][5] EyeYon CEO Nahum Ferera noted the IDE as "an important first step that requires the technology to go through strict testing in the US